Skip to main content

8 Result(s)

within A Mullally Remove this filter

and

  1. No Access

    Article

    Gain of function in Jak2V617F-positive T-cells

    G Nishanth, D Wolleschak, C Fahldieck, T Fischer, A Mullally, F Perner… in Leukemia (2017)

  2. No Access

    Article

    miR-433 is aberrantly expressed in myeloproliferative neoplasms and suppresses hematopoietic cell growth and differentiation

    BCR-ABL-negative myeloproliferative neoplasms (MPNs) are most frequently characterized by the JAK2V617F gain-of-function mutation, but several studies showed that JAK2V617F may not be the initiating event in M...

    X Lin, K L Rice, M Buzzai, E Hexner, F F Costa, O Kilpivaara, A Mullally… in Leukemia (2013)

  3. No Access

    Article

    EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L

    About 10% of patients with essential thrombocythemia (ET) or myelofibrosis (MF) that lack mutations in JAK2 harbor an activating mutation in the thrombopoietin receptor, MPLW515L. Distinct from the JAK2V617F r...

    G Wernig, M G Kharas, A Mullally, D S Leeman, R Okabe, T George, D O Clary… in Leukemia (2012)

  4. Article

    Open Access

    Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium

    Immediately following the 2010 annual American Society of Hematology (ASH) meeting, the 5th International Post-ASH Symposium on Chronic Myelogenous Leukemia and BCR-ABL1-Negative Myeloproliferative Neoplasms (MPN...

    A Tefferi, O Abdel-Wahab, F Cervantes, J D Crispino, G Finazzi… in Blood Cancer Journal (2011)

    Download PDF (299 KB) View Article

  5. No Access

    Article

    Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates

    TET2 (TET oncogene family member 2) is a candidate tumor suppressor gene located at chromosome 4q24, and was recently reported to be mutated in ∼14% of patients with JAK2V617F-positive myeloproliferative neoplasm...

    A Tefferi, R L Levine, K-H Lim, O Abdel-Wahab, T L Lasho, J Patel, C M Finke… in Leukemia (2009)

  6. No Access

    Article

    TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis

    High-throughput DNA sequence analysis was used to screen for TET2 mutations in bone marrow-derived DNA from 239 patients with BCR-ABL-negative myeloproliferative neoplasms (MPNs). Thirty-two mutations (19 framesh...

    A Tefferi, A Pardanani, K-H Lim, O Abdel-Wahab, T L Lasho, J Patel, N Gangat… in Leukemia (2009)

  7. No Access

    Chapter and Conference Paper

    Synchronous e-Learning: Three Perspectives

    Synchronous e-Learning is not well-described in the literature. A common complaint is that there is an absence of reported research in the area. Here are given the summary results from a number of synchronous ...

    J.A. Redmond, A. Parkinson, A. Mullally… in Innovations in E-learning, Instruction Tec… (2007)

  8. No Access

    Chapter and Conference Paper

    Use of a Web-based Teaching Collaborative Platform at Third Level: A Qualified Success?

    Web-based collaborative platforms appear to show significant potential for improving teaching and learning productivity and flexibility at Third Level. Two pilot studies were conducted at Trinity College Dubli...

    A. Mullally, A. Jennings, C. O’Connor… in Advances in Computer, Information, and Sys… (2006)